Postherpetic Neuralgia: Current Perspectives and Treatment Strategies
10.46518/kjnmd.2024.16.2.33
- Author:
Nam-Hee KIM
1
Author Information
1. Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
- Publication Type:Review Article
- From:
Korean Journal of Neuromuscular Disorders
2024;16(2):33-37
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Postherpetic neuralgia (PHN) is a chronic neuropathic pain syndrome that persists for more than three months after the resolution of herpes zoster rash. This condition affects approximately 30% of the population, primarily the elderly and immunocompromised individuals. PHN can be severely debilitating and often proves challenging to treat effectively. Recent advances in prevention and treatment have improved the management of PHN. The introduction of herpes zoster vaccines has shown promise in reducing the incidence of both herpes zoster and PHN. Current treatment guidelines recommend a multimodal approach, with effective therapies including tricyclic antidepressants, topical lidocaine, gabapentin, pregabalin, opioids, and topical capsaicin. This review focuses on optimizing treatment strategies and developing novel therapies to further enhance PHN management.
